Target intelligence / Profile preview

V-type proton ATPase 16 kDa proteolipid subunit c (ATP6V0C)

Target
ATP6V0C
Molecular classification
Enzyme, Transporter, Ion channel (proton channel component)
01

Overview

V-type proton ATPase 16 kDa proteolipid subunit c (ATP6V0C) is the c-subunit of the V0 sector of vacuolar H+-ATPase (V-ATPase), a multi-subunit enzyme complex responsible for ATP-dependent proton translocation across intracellular membranes in eukaryotes[1][4][6]. This action acidifies organelles like lysosomes, endosomes, and secretory vesicles, which is critical for numerous cellular processes including protein degradation, receptor-mediated endocytosis, synaptic vesicle loading, and pH regulation[1][3][5][7]. ATP6V0C forms the proteolipid c-ring structure within the V0 domain, acting as the core proton-conducting channel[3][7]. Disruption or mutation of ATP6V0C impairs organelle acidification and is associated with neurological defects (including epilepsy and febrile seizures) and has been implicated in cancer-related chemoresistance and cell migration[3][5]. Though V-ATPase inhibitors exist, selective targeting of ATP6V0C remains challenging due to its essential and ubiquitous roles[5][7].

Other names
ATP6CATP6LATPLVATLVma3VPPCEPEO3V-ATPase 16 kDa proteolipid subunit cVacuolar proton pump 16 kDa proteolipid subunit cATPase, H+ transporting, lysosomal 16 kDa, V0 subunit cH(+)-transporting two-sector ATPase 16 kDa subunitVacuolar ATP synthase 16 kDa proteolipid subunitVacuolar H+ ATPase proton channel subunit
02

Mechanism of action

Inhibition of proton translocation; Disruption of organelle acidification; Blockade of autophagic flux and lysosomal function

03

Biological functions

Intracellular organelle acidificationProtein sortingZymogen activationReceptor-mediated endocytosisSynaptic vesicle proton gradient generationRegulation of autophagic fluxmTOR signaling regulationIntracellular pH homeostasis
04

Disease associations

Neurological disorders (epilepsy, febrile seizures)CancerOther (disorders of acidification, neurodegeneration)
05

Safety considerations

Disruption leads to impaired lysosomal function, autophagic block, and cell deathPotential neurological dysfunction if inhibited systemicallyChallenges with targeting widely expressed, essential protein without systemic toxicity
06

Interacting drugs

bafilomycin A1 (selective V-ATPase inhibitor)

1 more in the full profile.

07

Biomarkers

no established clinical biomarkers, but alterations/mutations may have emerging research utility, particularly in neurology

Beyond the preview

Go deeper on V-type proton ATPase 16 kDa proteolipid subunit c (ATP6V0C).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on V-type proton ATPase 16 kDa proteolipid subunit c (ATP6V0C).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call